MASI:NGS-Masimo Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 152.15

Change

+0.47 (+0.31)%

Market Cap

USD 3.07B

Volume

0.46M

Analyst Target

USD 251.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Masimo Corp is a medical technology company. The Company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 23.46B
PODD Insulet Corporation

N/A

USD 17.22B
BRKR Bruker Corporation

N/A

USD 5.53B
IRTC iRhythm Technologies Inc

N/A

USD 3.28B
PRCT Procept Biorobotics Corp

N/A

USD 2.85B
TMDX TransMedics Group Inc

N/A

USD 2.73B
QDEL Quidel Corporation

N/A

USD 2.42B
LIVN LivaNova PLC

N/A

USD 1.95B
NVCR Novocure Ltd

N/A

USD 1.81B
UFPT UFP Technologies Inc

N/A

USD 1.62B

ETFs Containing MASI

EDOC:LSE Global X Telemedicine & D.. 4.72 % 0.00 %

N/A

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 4.72 % 0.00 %

N/A

USD 0.33M
DDOC:F Global X Telemedicine & D.. 4.72 % 0.00 %

N/A

N/A
EDOC:AU 4.09 % 0.00 %

N/A

N/A
WELL:PA HAN-GINS Indxx Healthcare.. 3.70 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.70 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 2.79 % 0.00 %

N/A

USD 0.01B
FDHT Fidelity Covington Trust .. 2.73 % 0.00 %

N/A

USD 7.77M
MUSC:CA Manulife Multifactor U.S... 0.74 % 0.62 %

N/A

CAD 3.66M
EQWM Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

N/A

N/A
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

N/A

USD 0.11B
PXMG 0.00 % 0.39 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.03B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.96% 74% C 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.96% 74% C 58% F
Trailing 12 Months  
Capital Gain 11.94% 82% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.94% 82% B 74% C
Trailing 5 Years  
Capital Gain -23.81% 71% C- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.81% 71% C- 32% F
Average Annual (5 Year Horizon)  
Capital Gain -5.91% 41% F 28% F
Dividend Return -5.91% 41% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.38% 76% C+ 53% F
Risk Adjusted Return -17.20% 36% F 26% F
Market Capitalization 3.07B 98% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.90 16% 10%
Price/Book Ratio 7.83 15% 15%
Price / Cash Flow Ratio 39.73 6% 6%
Price/Free Cash Flow Ratio 29.56 6% 12%
Management Effectiveness  
Return on Equity -25.23% 70% 41%
Return on Invested Capital -13.03% 61% 38%
Return on Assets 0.61% 84% 61%
Debt to Equity Ratio 69.20% 40% 31%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector